News Archive

  • 11.21.2019  |  T2 Biosystems wins CE Mark approval for diagnostic blood panel

    T2 Biosystems (NSDQ:TTOO) this week said it received CE mark approval for its T2Resistance Panel designed to detect 13 drug resistance genes in a blood sample.

    Full Story

  • 09.13.2019  |  T2 Biosystems jumps on $69m BARDA deal

    Lexington, Mass.-based T2 Biosystems signed a maximum $69 million funding deal with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research & Development Authority for the development of its MR-based diagnostic for sepsis-causing pathogens and antibiotic-resistance genes.

    Full Story

  • 03.01.2019  |  T2 Biosystems: FDA Grants breakthrough device designation for the T2Resistance Panel

    The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the T2Resistance Panel, a diagnostic tool that detects resistance markers from a single patient blood sample.

    Full Story